沙库巴曲缬沙坦在高血压治疗中的研究进展

Study of LCZ696 in Hypertension

沙库巴曲缬沙坦(LCZ696)是一种血管紧张素受体脑啡肽酶抑制剂类药物,国内外早已有其应用于慢性心力衰竭患者的指南,在2020年国际高血压学会(ISH)发布的最新版全球高血压实践指南中明确提出,血管紧张素受体脑啡肽酶抑制剂可替代血管紧张素转化酶抑制剂/血管紧张素Ⅱ受体阻滞剂用于高血压人群中射血分数降低性心力衰竭的治疗。在中国,心脑血管死亡人数占总死亡人数的40%,而高血压是第一危险因素。在对心力衰竭患者的随访中也发现,高血压是导致心力衰竭患者住院的首位原因。在中国因为人口老龄化,60岁以上的老年人中,高血压患病率有可能达到60%。现就其在高血压治疗方面的研究进行阐述。

LCZ696 is an angiotensin receptor enkephalin inhibitor(ARNI),which has been used in the guidance of chronic heart failure patients at home and abroad,and it was clearly proposed in the latest edition of Global Hypertension Practice Guidelines published by the International Society of Hypertension(ISH)in 2020 that ARNI can replace angiotensin converting enzyme inhibitor/angiotensinⅡreceptor blocker in the treatment of heart failure with reduced ejection fraction in hypertensive patients.Cardiovascular and cerebrovascular deaths account for 40%of the total number of deaths in China,and hypertension is the first risk factor.In the follow-up of patients with heart failure,it was also found that hypertension was the first cause of hospitalization of patients with heart failure.In China,because of the aging population,the prevalence of hypertension may reach 60%in the elderly over 60 years old.This article will review its research on the treatment of hypertension.